argenx SE - American Depositary Shares (ARGX)
ARGX moved a median of -0.02% 30 minutes after news, and -0.09% by the close. How ARGX actually reacts to news — the realized, point-in-time move the market made, measured across 249 labeled events over the last three years with zero look-ahead.
ARGX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.02% | 47% | 248 |
| 30-min | -0.02% | 48% | 249 |
| 60-min | -0.09% | 45% | 249 |
| to close | -0.09% | 48% | 244 |
| Middle 50% of ARGX reactions | -0.55% to +0.50% |
|---|---|
| Median reaction (30-min) | -0.02% |
| Measured reactions | 249 |
Half of all argenx SE - American Depositary Shares news events land between -0.55% and +0.50% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ARGX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 38 | -0.23% | 45% | 0.00% |
| Analyst downgrades | 29 | -0.10% | 41% | -0.15% |
| Coverage initiations | 12 | +0.27% | 75% | -0.07% |
| Rating reiterations | 204 | -0.00% | 50% | +0.02% |
| Price-target raises | 89 | -0.02% | 48% | +0.14% |
| Price-target cuts | 24 | +0.04% | 54% | -0.14% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how ARGX ranks against every other measured name →
That’s how ARGX usually reacts — get an email when it moves on news →Email me when ARGX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ARGX's baseline. Nothing else.
Recent ARGX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026 | Press release | GlobeNewswire | — | — | |
| ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law | Press release | Business Wire | +0.53% | -1.77% | |
| argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease | Press release | GlobeNewswire | -0.28% | -1.47% | |
| argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease | Press release | GlobeNewswire | -0.28% | -1.47% | |
| Form 6-K ARGENX SE For: Oct 08 | SEC filing · Form 6-K | SEC EDGAR | -0.28% | -1.47% | |
| argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline | Press release | GlobeNewswire | +0.23% | +0.58% | |
| Form 6-K ARGENX SE For: Sep 29 | SEC filing · Form 6-K | SEC EDGAR | +0.23% | +0.58% | |
| argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors | Press release | GlobeNewswire | +0.03% | -1.13% | |
| argenx to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.12% | -0.47% | |
| argenx Completes Acquisition of Forte Biosciences, Inc. | Press release | GlobeNewswire | -0.32% | +0.52% | |
| Form 6-K ARGENX SE For: Aug 27 | SEC filing · Form 6-K | SEC EDGAR | +0.02% | -2.66% | |
| argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis | Press release | GlobeNewswire | +4.36% | +6.72% | |
| Form 6-K ARGENX SE For: Aug 17 | SEC filing · Form 6-K | SEC EDGAR | +4.36% | +6.72% | |
| argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc. | Press release | GlobeNewswire | +0.48% | -0.04% | |
| argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026 | Press release | GlobeNewswire | -0.59% | +0.51% | |
| Form 6-K ARGENX SE For: Aug 03 | SEC filing · Form 6-K | SEC EDGAR | -0.59% | +0.51% | |
| argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline | Press release | GlobeNewswire | -0.29% | -2.86% | |
| Form 6-K ARGENX SE For: Jul 27 | SEC filing · Form 6-K | SEC EDGAR | -0.29% | -2.86% | |
| argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update | Press release | GlobeNewswire | -0.63% | +5.42% | |
| Form 6-K ARGENX SE For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -0.63% | +5.42% | |
| argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026 | Press release | GlobeNewswire | -0.56% | -0.42% | |
| argenx to Host Autoimmune Myositis R&D Webinar | Press release | GlobeNewswire | +0.12% | -7.04% | |
| Form 6-K ARGENX SE For: Jun 23 | SEC filing · Form 6-K | SEC EDGAR | +0.12% | -7.04% | |
| argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026 | Press release | GlobeNewswire | -0.49% | +1.75% | |
| Form 6-K ARGENX SE For: Jun 03 | SEC filing · Form 6-K | SEC EDGAR | -0.49% | +1.75% | |
| argenx to Host Myositis R&D Webinar on June 23, 2026 | Press release | GlobeNewswire | +0.72% | +2.13% | |
| argenx to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.06% | +0.41% | |
| Form 6-K ARGENX SE For: May 08 | SEC filing · Form 6-K | SEC EDGAR | +0.95% | +0.15% | |
| argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG | Press release | GlobeNewswire | +0.95% | +0.15% | |
| argenx Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -3.15% | -6.35% | |
| Form 6-K ARGENX SE For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | -3.15% | -6.35% | |
| argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer | Press release | GlobeNewswire | -3.15% | -6.35% | |
| argenx to Present at BofA Securities 2026 Health Care Conference | Press release | GlobeNewswire | -3.15% | -6.35% | |
| Form 6-K ARGENX SE For: May 06 | SEC filing · Form 6-K | SEC EDGAR | -3.15% | -6.35% | |
| argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026 | Press release | GlobeNewswire | +0.22% | -0.14% | |
| Form 6-K ARGENX SE For: Apr 20 | SEC filing · Form 6-K | SEC EDGAR | -0.53% | -1.50% | |
| argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP | Press release | GlobeNewswire | -0.53% | -1.50% | |
| argenx announces Annual General Meeting of Shareholders on May 6, 2026 | Press release | GlobeNewswire | +0.00% | -0.46% | |
| Form 6-K ARGENX SE For: Mar 20 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.46% | |
| Form 20-F ARGENX SE For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -0.18% | +0.42% | |
| Form 6-K ARGENX SE For: Dec 31 | SEC filing · Form 6-K | SEC EDGAR | -0.18% | +0.42% | |
| argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline | Press release | GlobeNewswire | -0.45% | +0.62% | |
| Form 6-K ARGENX SE For: Mar 06 | SEC filing · Form 6-K | SEC EDGAR | -0.45% | +0.62% | |
| argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis | Press release | GlobeNewswire | -3.20% | -3.70% | |
| argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update | Press release | GlobeNewswire | -3.20% | -3.70% | |
| Form 6-K ARGENX SE For: Dec 31 | SEC filing · Form 6-K | SEC EDGAR | -3.20% | -3.70% | |
| Form 6-K ARGENX SE For: Feb 26 | SEC filing · Form 6-K | SEC EDGAR | -3.20% | -3.70% | |
| argenx to Present at TD Cowen 46th Annual Healthcare Conference | Press release | GlobeNewswire | +1.27% | +0.58% | |
| argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026 | Press release | GlobeNewswire | -1.09% | +0.10% | |
| argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG | Press release | GlobeNewswire | +0.53% | +0.28% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ARGX section they belong to.
Where else ARGX is measured.
ARGX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Soligenix, Inc. (SNGX) | 251 | -0.71% | 35% |
| Co-Diagnostics, Inc. (CODX) | 250 | 0.00% | 46% |
| Array Technologies, Inc. (ARRY) | 249 | -0.24% | 41% |
| Cytosorbents Corporation (CTSO) | 249 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is argenx SE - American Depositary Shares's median reaction calculated?
Every labeled ARGX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 249 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of ARGX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ARGX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.